Relocating and expanding: Hyperway Pharma embarks on a new journey of development
Chengdu Hyperway Pharmaceutical Co., Ltd. (shortened as "Hyperway Pharma") has officially completed the expansion and relocation of its research and development offices, marking the beginning of a new phase of scaled, standardized, and capital-driven growth. The upgraded environment reflects a renewed image, strengthened capabilities, and an ambitious vision for the future.
Expansion sets sail, new environment empowers new development
From focused innovation within limited space to a significantly expanded footprint, Hyperway Pharma’s physical transformation mirrors its continuous advancement. This relocation represents a major upgrade aligned with the company’s long-term strategic plan and is the culmination of years of steady progress.
The new facility, carefully designed and thoughtfully planned, features spacious, open work areas, clearly defined functional zones, and comprehensive supporting infrastructure. These enhancements elevate operational efficiency and professionalism across both research and office functions, providing robust hardware support for business expansion, technological innovation, and talent development.
Steady progress and strong momentum across the R&D pipeline
Pipeline advancement remains the driving force behind Hyperway Pharma’s continued growth. Guided by the mission of "Better Medicines, Chinese Innovation", the company has assembled top-tier drug discovery talent, upheld rigorous scientific standards, and consistently delivered high-quality R&D outcomes.
- HBW-004285 (Nav1.8 inhibitor): The Phase II clinical trial of this novel, non-addictive analgesic is progressing rapidly, with most patients already enrolled. Emerging data show a favorable safety profile, excellent pharmacokinetics, and meaningful pain-relief effects in clinical use.
- HBW-012336 (KRAS G12D inhibitor): Clinical development is advancing smoothly. Enrollment and dosing have been completed across multiple cohorts, and the study has entered the mid-to-high dose range of the Phase I escalation stage. Available data indicate a favorable overall safety profile at all dose levels, laying a strong foundation for continued development.
- HBW-012462 (Pan-KRAS inhibitor): Designed to target multiple KRAS mutations, this program is progressing steadily through dose escalation. Clinical data show an overall favorable safety profile, with the latest cohort achieving a disease control rate of 80 percent, demonstrating promising therapeutic potential.
